Skip to main content
. Author manuscript; available in PMC: 2021 Jul 23.
Published in final edited form as: Genet Med. 2021 Mar 29;23(7):1281–1287. doi: 10.1038/s41436-021-01134-9

Figure 2: Patients with a MYBPC3 VUS identified as deleterious by STRUM (STRUM +) exhibit clinical outcomes similar to patients with a MYBPC3 pathogenic variants.

Figure 2:

Selection within SHaRe of patients with HCM and a single MYBPC3 pathogenic variant (MYBPC3 -Path-all) and patients with HCM without a sarcomere gene variant after clinical genotype analysis (Sarc -) is shown on the left. Kaplan Meier curves, median event free survival (median survival), and hazard ratio with corresponding 95% confidence interval (CI) reveal patients carrying a STRUM+ MYBPC3 VUS (red) exhibited overall composite outcomes similar to MYBPC3-Path-all patients (blue, p-value 0.5036). Whereas, patients carrying a STRUM- variant (black) exhibited a lower rate of adverse HCM-related outcomes (overall Composite) similar to Sarc- patients (grey).